About The IAVI Database of AIDS Vaccines In Human Trials
Download a Poster of Ongoing Trials of Preventive HIV Vaccines (This poster includes trials as of June 2006.) |
Vaccines and Trials
The IAVI database consists of two main tables of information: one about vaccines (products), including their design and composition, manufacture, etc.; and another about trials in which these vaccines have been tested or are being tested.
Variations of a given vaccine are classified as separate products. For example, the company VaxGen conducted Phase III trials on two different mixtures of the outer envelope protein from HIV, each based on different subtypes (genetic variant) of the virus; these are classified separately here.
The database includes vaccines in trials that are underway or completed, not those still under development in the laboratory, even if human testing has been scheduled. New vaccines are added upon receiving final official approval for a trial to begin.
Trials are identified by how far along they are: enrolling volunteers; fully enrolled and ongoing; or completed. This categorization is not made by IAVI but obtained from either the sources described below or from the trial organizer. Many organizers do not classify a trial as complete until analysis of all laboratory data is finished.
For more information
If you have questions about using the database, please contact iavireport@iavi.org. More information about AIDS vaccines and the International AIDS Vaccine Initiative is available at www.iavi.org.
Sources of information for the database
Most of the information on US-based trials was obtained from the ACTIS database of the US National Institutes of Health (NIH) or NIH publications of clinical trials. Information on trials sponsored by France’s ANRS (L'Agence Nationale de Recherches sur le SIDA, the French National Agency for AIDS Research) was kindly provided by Dr. Jean-Paul Levy. Trial information was also obtained from the HIV Vaccine Trials Network. Special thanks also to Barney Graham of the US government's Vaccine Research Center, who maintains a list of vaccine trials, which he shared with us prior to its being made public.
Many other individual investigators provided additional information. Our thanks to: Carlos Duarte Cano (Cuba), Raphaelle El Habib (Aventis-Pasteur), Thomas Evans (University of Rochester and AVEG/HIVNET investigator), Patricia Flynn, J. G. Guillet, Kelley Lennon, Slobod Karen, Sheena McCormack, Julie McElrath (University of Washington, Seattle, and HVTN investigator), Alice Melkonian, Merlin Robb (Walter Reed Army Institute of Research).